Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carles Pericay

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
BMJ Open|May 31, 2022
Patient experience, satisfaction and shared decision-making in colorectal cancer screening: protocol of the mixed-methods study CyDESAAnna Selva, Pilar López, Teresa Puig, et al.
Clinical Colorectal Cancer|November 6, 2013
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II studyJohanna C Bendell, Christophe Tournigand, Anna Swieboda-Sadlej, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 18, 2011
Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancerCarles Pericay Pijaume, Pilar Escudero Emperador, Román Bastús Piulats, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 8, 2022
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, et al.
International Journal of Colorectal Disease|February 17, 2020
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?Ruth Vera, Elena Mata, Encarna González, et al.
BMC Cancer|April 18, 2015
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological featuresRamon Salazar, Jaume Capdevila, Berta Laquente, et al.
BMC Cancer|November 28, 2020
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term resultsRamón Salazar, Jaume Capdevila, Jose Luis Manzano, et al.
British Journal of Cancer|August 1, 2019
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patientsElena Elez, Carles Pericay, Manuel Valladares-Ayerbes, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)Alfredo Carrato, Albert Abad, Bartomeu Massuti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 studyCarlos Fernández-Martos, Carles Pericay, Jorge Aparicio, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
BMJ Open|May 31, 2022
Patient experience, satisfaction and shared decision-making in colorectal cancer screening: protocol of the mixed-methods study CyDESAAnna Selva, Pilar López, Teresa Puig, et al.
Clinical Colorectal Cancer|November 6, 2013
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II studyJohanna C Bendell, Christophe Tournigand, Anna Swieboda-Sadlej, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 18, 2011
Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancerCarles Pericay Pijaume, Pilar Escudero Emperador, Román Bastús Piulats, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 8, 2022
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, et al.
International Journal of Colorectal Disease|February 17, 2020
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?Ruth Vera, Elena Mata, Encarna González, et al.
BMC Cancer|April 18, 2015
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological featuresRamon Salazar, Jaume Capdevila, Berta Laquente, et al.
BMC Cancer|November 28, 2020
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term resultsRamón Salazar, Jaume Capdevila, Jose Luis Manzano, et al.
British Journal of Cancer|August 1, 2019
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patientsElena Elez, Carles Pericay, Manuel Valladares-Ayerbes, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)Alfredo Carrato, Albert Abad, Bartomeu Massuti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 studyCarlos Fernández-Martos, Carles Pericay, Jorge Aparicio, et al.
Pageof 7